Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
87.30 USD | +0.02% |
|
-12.80% | -12.53% |
06:09am | TD Cowen Downgrades Merck & Co. to Hold From Buy, Adjusts Price Target to $100 From $121 | MT |
Feb. 07 | Health Rounds: Vaccine keeps advanced kidney cancer from recurring | RE |
Business description: Merck & Co., Inc.
- sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (22.1%);
- sale of animal health products (9.4%);
- other (1.5%).
Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).
Number of employees: 71,000
Sales by Activity: Merck & Co., Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Pharmaceutical | 41.75B | 43.02B | 42.75B | 52B | 53.58B |
Animal Health | 4.39B | 4.7B | 5.57B | 5.55B | 5.62B |
Unallocated Other Revenues | 521M | 247M | 382M | 1.73B | 907M |
Other profits | 175M | 23M | - | - | - |
Geographical breakdown of sales: Merck & Co., Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
United States | 20.32B | 21.03B | 22.42B | 27.21B | 28.48B |
Europe, Middle East and Africa | 12.71B | 13.6B | 13.34B | 14.49B | 13.25B |
China | 3.21B | 3.62B | 4.38B | 5.19B | 6.8B |
Asia Pacific (other than China and Japan) | 2.94B | 2.86B | 2.41B | 3.61B | 3.22B |
Japan | 3.58B | 3.38B | 2.73B | 3.63B | 3.16B |
Latin America | 2.47B | 2.27B | 2.21B | 2.58B | 3.09B |
Other | 1.61B | 1.23B | 1.22B | 2.57B | 2.1B |
Managers: Merck & Co., Inc.
Director | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 58 | 2021-06-30 |
Director of Finance/CFO | 56 | 2021-03-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 56 | 2020-07-31 |
Joseph Romanelli
IRC | Investor Relations Contact | 51 | 1995-12-31 |
Peter Dannenbaum
IRC | Investor Relations Contact | - | 2017-06-30 |
Members of the board: Merck & Co., Inc.
Manager | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 64 | 2007-11-26 |
Patricia Russo
BRD | Director/Board Member | 72 | 1995-08-31 |
Robert Davis
CHM | Chairman | 58 | 2022-11-30 |
Pamela Craig
BRD | Director/Board Member | 68 | 2015-08-31 |
Paul Rothman
BRD | Director/Board Member | 66 | 2015-08-31 |
Inge Thulin
BRD | Director/Board Member | 70 | 2018-02-28 |
Mary Coe
BRD | Director/Board Member | 58 | 2019-03-17 |
Kathy Warden
BRD | Director/Board Member | 53 | 2020-03-15 |
Director/Board Member | 72 | 2020-03-15 | |
Director/Board Member | 70 | 2020-05-25 |
Holdings: Merck & Co., Inc.
Name | Equities | % | Valuation |
---|---|---|---|
13,443,693 | 10.23% | 274,889,375 $ | |
PERSONALIS, INC. 19.78% | 14,044,943 | 19.78% | 73,314,602 $ |
1,739,768 | 4.65% | 23,382,482 $ |
Company details: Merck & Co., Inc.

Group companies: Merck & Co., Inc.
Name | Category and Sector |
---|---|
Organon (India) Pvt Ltd.
![]() Organon (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Organon India Pvt Ltd. manufactures and distribution of pharmaceutical preparations. The company is headquartered in Mumbai, India. |
Pharmaceuticals: Major
|
Organon LLC
| |
Merck International Holdings LLC
| |
Merck Holdings, Inc.
| |
Merck Sharp & Dohme Manufacturing Unlimited Co.
|
Other Pharmaceuticals
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.87% | -11.68% | -30.43% | +14.05% | 221B | ||
+0.91% | +8.29% | +18.66% | +261.04% | 791B | ||
-0.90% | +3.99% | -24.92% | +81.83% | 387B | ||
-0.25% | +0.64% | -2.32% | -10.71% | 369B | ||
-1.23% | +3.64% | +9.49% | +33.10% | 337B | ||
-0.81% | +0.28% | +25.93% | -19.39% | 255B | ||
+0.09% | +3.17% | +22.45% | +34.50% | 223B | ||
+0.30% | +0.95% | +10.63% | +21.02% | 210B | ||
-1.42% | +2.84% | +0.83% | +23.76% | 158B | ||
-0.35% | -2.94% | -6.60% | -49.99% | 146B | ||
Average | -0.38% | +0.90% | +2.37% | +38.92% | 309.6B | |
Weighted average by Cap. | -0.35% | +2.55% | +4.45% | +81.40% |
Sector

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
- Company Merck & Co., Inc.